Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's dise
| Agency | National Institutes of Health |
|---|---|
| Status | Forecasted |
| Opportunity number | FOR-RFA-AG-26-019 |
| Posted date | 06/27/2025 |
| Assistance Listing (CFDA) | 93.866 |
| Description | The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. Working with the ACTC is a collaborative venture between the applicant, NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. The work of this NOFO will enable the testing of interventions that target deleterious cognitive and neuropsychiatric changes associated with age-relat |
| Agency contact | ryanl@mail.nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/359857 |